Large-scale cardiovascular outcome trials have demonstrated that certain GLP-1 RAs, such as liraglutide and semaglutide, not only provide cardiovascular benefits but also reduce the risk of major adverse cardiovascular events in high-risk patients with T2DM. This evidence concerns the gene GCG and type 2 diabetes mellitus.